INVION LIMITED — Director's Dealing 2010

Mar 24, 2010

==> picture [594 x 106] intentionally omitted <==

25 March 2010

The Manager Company Announcements Office ASX Limited 20 Bridge St SYDNEY NSW 2000

Dear Sir,

APPENDIX 3Y

On 23 March 2010 a CBio Limited shareholder, Australian Technology Innovation Fund Limited, conducted an inspecie distribution of its CBio holding to its members.

Mr Stephen Jones, Dr Michael Monsour and Mr Stephen Streeter are shareholders in Australian Technology Innovation Fund Limited and received CBio shares as part of this in-specie distribution.

Appendix 3Y’s in relation to the distribution are attached to this notice.

For and on behalf of the Board

==> picture [85 x 64] intentionally omitted <==

BEN GRAHAM Company Secretary

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity CBIO LIMITED ABN 76 094 730 417

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	MR STEPHEN JONES
Date of last notice	17 FEBRUARY 2010

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct – Mr Stephen Jones Indirect-described below
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	1. Stephen George Burch Jones & Nadine Jones A/C> 2. Australian Technology Innovation Fund Limited. 3. Australian Biofunds Investments Limited 4. Emrold Pty Ltd Trust> Mr Jones is a beneficiary of the S & N Super Fund (at 1 above) and is a Director and shareholder of the entities identified at 2,3&4.
Date of change	23 March 2010

• See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

No. of securities held prior to change	1. Stephen Jones 33 ordinary shares 2. Stephen George Burch Jones & Nadine Jones A/C> 1,190,000 ordinary shares and 300,000 share options 3. Australian Technology Innovation Fund Limited 3,373,598 ordinary shares 4. Australian Biofunds Investments Limited 199,553 ordinary shares 5. Emrold Pty Ltd < ATF Jones Family Trust > nil
Class	Ordinary
Number acquired	Stephen Jones: 6 Emrold Pty Ltd : 424,520
Number disposed	Australian Technology Innovation Fund Limited: 3,004,843 ordinary shares
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	38 cents per share based on closing share price 23 March 2010.
No. of securities held after change	1. Stephen Jones 39 ordinary shares 2. Stephen George Burch Jones & Nadine Jones A/C> 1,190,000 ordinary shares and 300,000 share options 3. Australian Technology Innovation Fund Limited 368,755 ordinary shares 4. Australian Biofunds Investments Limited 199,553 ordinary shares 5. Emrold Pty Ltd < ATF Jones Family Trust > 424,520
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Shares acquired by Mr Stephen Jones and associated entities were part of an in-specie distribution conducted by Australian Technology Innovation Fund Limited.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	n/a
Interest after change	n/a

• See chapter 19 for defined terms.

Appendix 3Y Page 3

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity CBIO LIMITED ABN 76 094 730 417

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	MR STEPHEN STREETER
Date of last notice	17 FEBRUARY 2010

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	1. S & M Streeter Investments Co Pty Ltd. 2. Australian Technology Innovation Fund Limited. 3. Australian Biofund Investments Limited Mr Streeter is a Director and shareholder of the entities identified above.
Date of change	23 March 2010
No. of securities held prior to change	1. S & M Streeter Investments Co Pty Ltd: 105,682 ordinary shares & 1,550,000 share options. 2. Australian Technology Innovation Fund Limited: 3,373,598 ordinary shares 3. Australian Biofund Investments Limited- 199,553 ordinaryshares
Class	Ordinary
Number acquired	S & M Streeter Investments Co Pty Ltd: 150,907 ordinary shares
Number disposed	Australian Technology Innovation Fund Limited: 3,004,843 ordinary shares

• See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	38 cents per share based on closing share price 23 March 2010.
No. of securities held after change	1. S & M Streeter Investments Co Pty Ltd: 256,589 ordinary shares & 1,550,000 share options. 2. Australian Technology Innovation Fund Limited: 368,755 ordinary shares 3. Australian Biofund Investments Limited:199,553ordinaryshares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Shares acquired by S & M Streeter Investments Co Pty Ltd were part of an in- specie distribution conducted by Australian Technology Innovation Fund Limited.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	n/a
Interest after change	n/a

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity CBIO LIMITED ABN 76 094 730 417

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	DR MICHAEL MONSOUR
Date of last notice	17 FEBRUARY 2010

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct: Dr Michael Monsour Indirect: Described below
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	1. MP Monsour Medical Practice Pty Ltd Superannuation Fund A/C> 2. MPAMM Pty Ltd 3. Australian Technology Innovation Fund Limited. 4. Australian Biofunds Investments Limited Dr Monsour is a Director and shareholder of the entities identified above. 5. Dr Michael Monsour Foundation A/C> Due to an administrative error, Dr Monsour is currently the registered holder of the Spyder Foundation holding in CBio. This error is currently being rectified by Dr Monsour and will result in a further Appendix3Y in due course.
Date of change	23 March 2010

• See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

No. of securities held prior to change	1. MP Monsour Medical Practice Pty Ltd Superannuation\ Fund\ A/C> 1,050,208 ordinary shares and 1,490,000 share options 2. MPAMM Pty Ltd 4,134,074 ordinary shares and 1,614,000 share options 3. Australian Technology Innovation Fund Limited 3,373,598 ordinary shares 4. Australian Biofunds Investments Limited 199,553 ordinary shares 5. Dr Michael Monsour Foundation A/C> nil
Class	Ordinary
Number acquired	1. Dr Michael Monsour 38,187 ordinary shares 2. MP Monsour Medical Practice Pty Ltd Superannuation Fund A/C> 7,272 ordinary shares 3. MPAMM Pty Ltd 173,516 ordinary shares 4. Dr Michael Monsour Foundation A/C> 337,843
Number disposed	Australian Technology Innovation Fund Limited: 3,004,843 ordinary shares
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	38 cents per share based on closing share price 23 March 2010.
No. of securities held after change	1. Dr Michael Monsour 38,187 ordinary shares 2. MP Monsour Medical Practice Pty Ltd Superannuation\ Fund\ A/C> 1,057,480 ordinary shares and 1,490,000 share options 3. MPAMM Pty Ltd 4,307,590 ordinary shares and 1,614,000 share options 4. Australian Technology Innovation Fund Limited 368,755 ordinary shares 5. Australian Biofunds Investments Limited 199,755 ordinary shares 6. Dr Michael Monsour Foundation A/C> 337,843

• See chapter 19 for defined terms. Appendix 3Y Page 2

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

	Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Shares acquired Dr Michael Monsour and associated entities were part of an in-specie distribution conducted by Australian Technology Innovation Fund Limited.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	n/a
Interest after change	n/a

• See chapter 19 for defined terms.

Appendix 3Y Page 3

11/3/2002